Curcumin, the natural pigment that gives the spice turmeric its yellow color, has increasingly come under the scientific spotlight in recent years, with studies investigating its potential health benefits.
As a result, curcumin has been linked to a range of health benefits, including potential protection against prostate cancer, Alzheimer’s, protection against heart failure, diabetes, and arthritis.
Sabinsa’s new ingredient - Curcumin C3 Reduct - will be launched at the upcoming Engredea show in Anaheim, and the company is expecting big things of its patented and clinically safe 95% tetrahydrocurcuminoids ingredient.
Recent research into metabolites of curcuminoids have unraveled the role of tetrahydrocurcuminoids as not only the major metabolites but also pharmacologically superior to curcuminoids themselves, said the company.
Shaheen Majeed, Sabinsa marketing director, told us: “With curcumin the major hurdle in obtaining better dosage efficiency has been limited bioavailability. Curcumin C3 Reduct resolves this issue as well as manufacturing limitations.
“Certainly removing the major barriers in increasing curcumin’s acceptance in the market allows it to finally achieve the potential that we have all known is there. Curcumin is one of the most searched topics in medical databases, and the body of science, much of which was done on C3 Complex, is quite impressive.
“Curcumin is on the radar of the medical community, and given that many of the conditions it addresses are ubiquitous, we fully expect this product to be the next omega-3.”
Color & cost
Majeed added that the vivid color of curcumin is a manufacturing nightmare for many companies, but the Curcumin C3 Reduct is a white powder. The ingredient will also allow formulators to increase dosage efficiency, meaning smaller capsules and tablets for consumers, while retaining greater potency, stability and much better bioavailability, he said.
“This is the best thing to happen to curcumin since our original curcumin. It’s a game changer for the industry.”
Commenting on the dosing efficiency, the company said that its recommended Curcumin C3 Complex dosage is 1500mg/daily, but the new Curcumin C3 Reduct is recommended at 400mg/daily.
“Cost savings will be a major advantage with improved dosage efficiency of this product in comparison to regular curcumin in the market,” Majeed told NutraIngredients-USA.
The ingredient, which is available globally, can be formulated in various delivery systems like tablets, capsules, softgels, he added. “In fact, with better stability at physiological pH and photostability, this product can be used in liquid formulations also.”
Curcumin C3 Reduct is covered by these strictly enforced patents: US6653327, AU2006235807, EP1171144, EP1328263, NZ514884, US8119696, and JP2000-610495. It is Kosher and Halal certified, and allergen-free.